argenx reported a breakout 2025: $4.2 billion in global product net sales for the year, up 90% year over...

Recursion reported fourth quarter and full-year 2025 results with a pivotal operational milestone: the company delivered its first AI-enabled...

Cardiff Oncology reported a positive randomized phase 2 readout in first-line RAS-mutated metastatic colorectal cancer, selecting the 30 mg...

Supernus Pharmaceuticals posted record fourth-quarter and full-year 2025 revenues, buoyed by newer CNS assets and the integration of Sage...

Vaxcyte has launched a comprehensive phase 3 program for VAX-31, its 31-valent pneumococcal conjugate vaccine, with head-to-head noninferiority testing...

BridgeBio Pharma reported $154.2 million in fourth-quarter revenues and $502.1 million for full-year 2025, propelled by ATTRuby’s first full...

Myriad Genetics closed 2025 with flat fourth-quarter revenue at $209.8 million, a 70% gross margin, and a modest GAAP...

Telix Pharmaceuticals reported full-year 2025 revenue of US$803.8 million, up 56% year over year, and issued 2026 guidance of...

Amicus Therapeutics posted 2025 revenue of $634.2 million, up 20% reported and 17% at constant exchange rates, anchored by...

Galapagos has executed a strategic reset alongside its full-year 2025 results, moving to wind down its cell therapy business,...